

CLINICAL REPORT

Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic PruritusNgoc Quan PHAN¹, Christine BLOME², Fleur FRITZ³, Joachim GERSS⁴, Adam REICH⁵, Toshi EBATA⁶, Matthias AUGUSTIN², Jacek C. SZEPIETOWSKI⁵ and Sonja STÄNDER¹¹Clinical Neurodermatology, Department of Dermatology and Competence Center Chronic Pruritus, ²Department of Medical Informatics, ⁴Institute of Biostatistics and Clinical Research, University Hospital Münster; ³Center for Dermatological Research (CeDeF), Health Economics and QoL Research Group, German Center for Health Services Research in Dermatology (CVderm), University Hospital Eppendorf, Germany; ⁵Department of Dermatology, Venereology and Allergology, Wrocław Medical University, Poland, and ⁶Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan

The most commonly used tool for self-report of pruritus intensity is the visual analogue scale (VAS). Similar tools are the numerical rating scale (NRS) and verbal rating scale (VRS). In the present study (initiated by the International Forum for the Study of Itch) assessing reliability of these tools, 471 randomly selected patients with chronic itch (200 males, 271 females, mean age 58.44 years) recorded their pruritus intensity on VAS (100-mm line), NRS (0–10) and VRS (four-point) scales. Re-test reliability was analysed in a subgroup of 250 patients after one hour. Statistical analysis showed a high reliability and concurrent validity ($r > 0.8$; $p < 0.01$) for all tools. Mean values of all scales showed a high correlation. In conclusion, high reliability and concurrent validity was found for VAS, NRS and VRS. On re-test, higher correlation and less missing values were observed. A training session before starting a clinical trial is recommended. Key words: itch; measurement tools; clinical trial; International Forum for the Study of Itch; concurrent validity.

(Accepted August 3, 2011.)

Acta Derm Venereol 2012; 92: 502–507.

Sonja Ständer, Competence Center Chronic Pruritus, Department of Dermatology, University Hospital Münster, Von-Esmarch-Str. 58, DE-48149 Münster, Germany. E-mail: sonja.staender@uni-muenster.de

Chronic pruritus is a frequent symptom with a prevalence of approximately 17% in adults, which occurs in dermatological, systemic, neurological, and psychiatric diseases (1). During the past years, new findings in the neurobiology of pruritus have enabled the development of new therapies, leading to a growing number of clinical trials worldwide (2). To date, there is no clear definition or straightforward recommendation of measurement tools for the study of pruritus. Although it is still difficult to objectively assess all the attributes of pruritus, obtaining information on the intensity, severity and course of pruritus in a consistent way is essential for the baseline assessment of the symptom, evaluation of the treatment

efficacy and comparability of studies. Although various methods have been described to evaluate pruritus (Table I), validation of these instruments in chronic pruritus is still pending. The International Forum for the Study of Itch (IFSI) established a special interest group (SIG) for the evaluation and harmonization of measurement tools for clinical trials (www.itchforum.net). In this first study, the aim was to investigate the reliability and validity (criterion, concurrent and construct validity) and the internal consistency (Cronbach's alpha) of three pruritus intensity scales; namely, the visual analogue scale (VAS), numerical rating scale (NRS) and verbal rating scale (VRS) in patients with chronic pruritus.

PATIENTS AND METHODS

Over a period of 7 months, a consecutive collective of 471 randomly selected patients (200 males, 271 females, range 16–92 years, mean age 58.44 years with standard deviation (SD) of 15.68 years) with chronic pruritus (> 6 weeks) of any origin were included in the study. According to the classification of the IFSI (3), patients were grouped according to the clinical appearance of the skin as follows: pruritus on non-inflamed skin ($n = 272$); pruritus on inflamed skin ($n = 83$); pruritus with chronic scratch lesions ($n = 116$).

Patients were asked to record their current pruritus intensity (over the last 24 h) on a VAS on a horizontal 100-mm line, on a NRS from 0 to 10 and on a four-point VRS on a questionnaire (Fig. 1) (visit (V) 1). For test-retest reliability, 250 of 471 patients (102 males, 148 females, range 16–91 years, mean age \pm SD 55.95 \pm 16.68 years) recorded their pruritus intensity again on a questionnaire with a different order of the scales 1 hour later (V2). Fifty-two of 250 patients (25 males, 27 females, range 24–88 years, mean age 59.08 \pm 14.61 years) completed the pruritus intensity scales again after 3–8 weeks (V3). If patients did not complete one scale this was defined as a “missing value”.

The study was approved by the local ethics committee of the University of Münster. Patients gave written informed consent for clinical data collection and analysis.

Assessment scales

The VAS, first developed in 1921 by Hayes & Patterson (4), is commonly used to measure, for example, panic, depression, fatigue and pain (4–8). To assess the intensity of pruritus, a VAS is also the most commonly used tool. For example, VAS

Table I. Referenced assessment of pruritus: patient self-reporting (scales and questionnaires) and scratching measurement tools

Category	Name	Author	
<i>Scales of pruritus intensity</i>			
Multidimensional scale	Pruritus grading system	Szepietowski & Schwartz (18)	
	5-D Pruritus Scale	Elman et al. (19)	
	Itch Severity Scale	Majeski et al. (20)	
	Unidimensional scales	Visual analogue scale (VAS)	Wahlgren (21), Reich et al. (17), Phan & Ständer (22)
		Numeric rating scale (NRS)	Jenkins et al. (23)
	Verbal rating scale (VRS)	Wahlgren et al. (24, 25) Jenkins et al. (23)	
<i>Questionnaires</i>			
Pruritus questionnaires (PQ)	Eppendorf PQ	Darsow et al. (26)	
	The short-form of McGill PQ	Yosipovitch et al. (27)	
	Heidelberg PQ	Weisshaar et al. (28)	
	NeuroDerm PQ	Ständer (29)	
Quality of life	DLQI	Finlay & Khan (30)	
	Itchy-QoL	Desai et al. (31)	
Anxiety, depression	HADS	Zigmond & Snaith (32)	
Patients' needs	Patient benefit index – Pruritus (PBI-p)	Blome et al. (33)	
<i>Measurement of scratching</i>			
Observation of excoriations and lichenifications	(scratch symptom score- under development)	Ständer, Augustin (unpublished)	
Movement measurement	Wrist movement	Accelerometer	Benjamin et al. (34)
		Actigraphy	Bringhurst et al. (35)
		DigiTrac	Hon et al. (36)
		ActiTrac	Ebata et al. (37)
Forehand movement		Electromyogram	Savin et al. (38)
		Paper gauge	Aoki et al. (39)
Scratch movements of the hand		Pressure sensor	Endo et al. (40)
		Scratch radar	Mustakallio (41)
		Movement sensors	Summerfield & Welch (42), Felix & Shuster (43)
Limb movement		Movement sensors	Felix & Shuster (43)
		Infrared video recording	Ebata et al. (44)
Whole body movement		Piezo film technology	Talbot et al. (45); Molenaar et al. (46)
		Pruritometer 2	Bijak et al. (47)
		(Piezo sensor)	
<i>Measurement of itch using technical devices</i>			
Perceptual matching		Stener-Victorin et al. (48)	
Assessment reminder	Symtrack	Hägermark & Wahlgren (49)	

is part of the SCORAD (SCORing Atopic Dermatitis) in atopic dermatitis (9). VAS is a graphic tool with a 100-mm horizontal line with the left end marked as "no symptom" and the right end marked as "worst imaginable symptom" (Fig. 1). The patient is asked to draw a vertical line to indicate the horizontal scale at a point that corresponded to the intensity of the symptom. The length from the left end to the vertical mark made by the patient is measured in millimetres. Separation in one-hundredths is regarded as sufficiently sensitive (10). The NRS is a similar tool and has also been validated for the measurement of pain (8).




Fig. 1. Assessment scales: visual analogue scale (VAS), numerical rating scale (NRS) and verbal rating scale (VRS).

Patients were asked to assign a numerical score representing the intensity of their symptoms on a scale from 0 to 10, with 0 having no symptoms and 10 having worst imaginable symptoms. The VRS consists of a list of adjectives describing different, usually four, levels of symptom intensity, e.g. 0 = none, 1 = mild, 2 = moderate and 3 = severe/intense (8).

Statistical analysis

SPSS 18.0 was used for statistical analysis of data.

Criterion validity. Concurrent validity measures how well the scale correlates with other (ideally gold standard) measures of the same variable (11, 12). For this analysis, we did not have a gold standard; correlation coefficients were estimated between the three instruments used to measure pruritus intensity. Inspecting QQ-plots and histograms we found that none of the VAS, NRS and VRS data were normally distributed. Therefore, Spearman's correlation coefficients were estimated between all three instruments. In addition, we also investigated Cronbach's alpha.

Construct validity. The extent to which a particular measure performs in accordance with theoretical expectations is known as construct validity (12, 13). It can be expected that the scores of VAS, NRS and VRS all increase with pruritus intensity. This should be similar in different subgroups of chronic pruritus

patients. We therefore expect a similar correlation and increased scores in accordance with pruritus intensity in the 3 different clinical groups according to IFSI (3). Spearman's correlation coefficients were estimated between all 3 instruments. In addition, we also investigated Cronbach's alpha.

Re-test reliability. If between two time-points, a patient's status that might affect the parameter being measured does not change, then measurements taken at these times should be the same, or very similar. Given that pruritus intensity varies over the day and is influenced by factors such as mood, treatment, and activity level, we chose to estimate re-test reliability one hour after the first assessment.

Due to the fact that the VRS is ordinal scaled and VAS and NRS are metrical scaled, the intraclass correlation coefficients (ICC) were determined for the reliability of the three scales after one hour. In the case of the VRS, for reasons of comparability both the Kappa and the ICC coefficient were determined. In general, test-retest reliability coefficients above 0.9 are considered as high, and between 0.7 and 0.8 are considered as acceptable for research tools (12).

RESULTS

Missing values

If patients did not complete one scale this was defined as a "missing value". Most patients completed the NRS and VRS (Table II). The highest number of missing values could be observed in the VAS assessment. At V1, 12.5% of 471 patients did not record their pruritus intensity on VAS, 4.2% on NRS and 7.2% on VRS. After repeat assessment, fewer missing values could be observed in V2 and V3. Age-dependent analysis of missing values in patients <60 years, compared with patients ≥60 years at V1 showed that there are nearly twice as many missing values in VAS and NRS assessments in elderly patients than in patients under the age of 60 years (Table II). Interestingly, VRS showed a lower number of missing values in the elderly population.

Assessment of pruritus intensity using VAS, NRS and VRS

Of the 471 randomly selected patients with chronic pruritus, 36 (7.6%) reported currently having no pruritus on the VRS ("0"), which correlated with a mean VAS

Table II. Missing values: percentage of patients with chronic pruritus who did not complete visual analogue scale (VAS), numerical rating scale (NRS) or verbal rating scale (VRS)

n	Visit	Missing values (%)		
		VAS	NRS	VRS
471	V1	12.5	4.2	7.2
	<60 years	20/229, 8.7	12/229, 5.2	11/229, 4.8
	≥60 years	39/242, 16.1	22/242, 9.1	9/242, 3.7
250	V1	13.6	4.0	7.6
	V2	8.0	2.4	5.2
52	V1	17.3	5.8	5.8
	V2	9.6	7.7	11.5
	V3	13.5	0.0	1.9




Fig. 2. Correlation of verbal rating scale (VRS) with mean numerical rating scale (NRS) and visual analogue scale (VAS) (all patients $n=471$; V1).

value of 0.18 points and an NRS value of 0.10 points (Fig. 2). A total of 189 patients (40.1%) reported having low intensity ("1") pruritus (mean VAS/mean NRS: 1.90/2.28), 174 patients (37.0%) moderate ("2") pruritus (mean VAS/mean NRS: 5.12/5.52), and 38 patients (8.1%) severe ("3") pruritus (mean VAS/mean NRS: 8.57/8.93), while 34 patients (7.2%) did not complete the VRS (Table II). NRS values were slightly higher than VAS values (Fig. 2). Comparison of VAS and NRS with VRS showed a high correlation with similar mean values of VAS and NRS. Comparison of pruritus ratings according to gender and age (patients <60 years vs. ≥60 years) showed no significant difference between men and women (VAS, $p=0.340$; VRS, $p=0.496$; NRS, $p=0.841$) nor between older (≥60 years) and younger (<60 years) patients (VAS, $p=0.934$; VRS, $p=0.201$; NRS, $p=0.335$).

Mean VRS values were almost identical in the three clinical groups (Fig. 3). Interestingly, NRS and VAS values were slightly higher in patients with pruritus on inflamed skin (i.e. dermatoses) than in the two other groups. In patients with pruritus on non-inflamed skin and pruritus with chronic scratch lesions, NRS values were slightly higher than VAS values, as observed also in the analysis of the total cohort (Fig. 2); the opposite was the case in patients with pruritus on inflamed skin (i.e. dermatoses).

Concurrent validity

Correlation of VAS, NRS and VRS by Spearman's correlation coefficient showed statistically significant high values. In particular, correlation of VAS with NRS showed high correlation coefficients ($r > 0.8$; $p < 0.01$) at each visit (V1–V3). After repeat assessment, higher




Fig. 3. Assessment of pruritus intensity in different clinical groups of chronic pruritus at V1: pruritus on non-inflamed skin (normal skin); pruritus on inflamed skin (dermatoses) and pruritus with chronic scratch lesions (e.g. prurigo nodularis).

correlations could be observed (Table III). In addition to the Spearman’s correlation coefficient, also Cronbach’s alpha showed qualitatively similar high values (Table III).

Re-test reliability

Statistical correlation of the one hour difference showed high values between 0.74 and 0.80. The NRS showed the best reliability, with an intraclass correlation coefficient (ICC) of 0.801. The ICC of VAS was 0.749 and of VRS 0.740. We also performed Kappa’s level of agreement in the ordinal scaled VRS, which was 0.643.

Nevertheless, correlation of the scales and their values after one hour was not very high ($r < 0.900$), possibly due to slightly different evaluation/rating after reflecting on pruritus intensity.

DISCUSSION

Pruritus is a subjective symptom with multiple dimensions that cannot be measured objectively to

date. Also, scratch lesions cannot serve as a mirror for pruritus severity, since a broad inter-individual variety can be observed. Therefore, the best option is to let the patient report the symptoms, for example pruritus intensity, as he or she values them. In our study, a total of 471 chronic pruritus patients were asked to record their pruritus intensity on the VAS, NRS and VRS. Statistical analysis showed a high reliability and concurrent validity ($r > 0.8$; $p < 0.01$) for all tools. Mean values of all scales showed a high correlation. Low pruritus (VRS = 1) was equivalent to a mean VAS value of 1.9 and mean NRS value of 2.3; moderate pruritus (VRS = 2) was equivalent to a mean VAS value of 5.1 and mean NRS 5.5, severe pruritus (VRS = 3) was equivalent to a mean VAS value of 8.57 and mean NRS 8.93. These data show a high discrimination sensitivity of VAS and NRS values. However, a tendency to the middle of the VAS and NRS scales can be observed in the category moderate pruritus (VAS/NRS values of around 5). This tendency is frequently observed in daily routine and hampers interpretation of the pruritus intensity. In our study, all patients were Caucasians. It is speculated that other ethnic groups experience other itch intensities (e.g. lower itch ratings in Japanese patients compared with Caucasians; Reich A et al. unpublished observation; 14). A comparative study concerning the various intensity scales between different ethnic groups is pending. Moreover, in our study, we did not observe differences in monitoring itch intensity related to age, gender or clinical patient group, except the observation that men tend to rate itch intensity slightly higher than women.

Patients repetitively assessed the different scales. A high reproducibility of the scales with consistent values after a short interval of assessment is desirable. This item can be tested if patients complete the scales twice within a short period of time (re-test reliability). Re-test reliability testing was performed in 250 patients. VAS, NRS and VRS were repeated one hour after the first assessment. The intraclass correlation coefficient for the three scales varied between 0.741 and 0.801. In acute pain studies, a correlation coefficient between 0.97 and 0.99 was achieved showing a high reliability (15). The

Table III. Concurrent validity: Spearman’s correlation coefficients and Cronbach’s α between visual analogue scale (VAS), numerical rating scale (NRS) and verbal rating scale (VRS)

n	Visit	VAS–NRS		VAS–VRS		NRS–VRS	
		Spearman’s correlation coefficient	Cronbach’s α	Spearman’s correlation coefficient	Cronbach’s α	Spearman’s correlation coefficient	Cronbach’s α
471	V1	0.865*	0.935	0.752*	0.541	0.847*	0.604
250	V1	0.827*	0.899	0.699*	0.481	0.809*	0.571
	V2	0.884*	0.936	0.811*	0.584	0.837*	0.615
52	V1	0.829*	0.920	0.644*	0.411	0.732*	0.487
	V2	0.892*	0.945	0.819*	0.538	0.768*	0.515
	V3	0.960*	0.980	0.854*	0.624	0.888*	0.655

* $p < 0.01$.

authors scored pain in an interval of one minute instead of one hour, possibly explaining the higher correlation coefficient (15). In general, pruritus intensity can be influenced by a variety of external and internal factors, such as worsening by stress or weather. Changes may occur quickly, explaining variations even within one hour. Given that in our study 24.4% of patients with chronic pruritus were over 70 years of age, cognitive impairment cannot be ruled out in one or another individual case. However, we found a high correlation between the first and second assessment in all scales. The sensitivity of VAS, NRS and VRS to detect clinically relevant changes and the minimal clinically important difference (MCID) in pruritus intensity, either worsening by bothersome factors or improvement by therapies, has not been investigated and no conclusions can be drawn on this issue from this study. The assumption behind the use of VAS is that it is possible to grade a phenomenon on a linear scale from one extreme to another. However, it has to be assumed that the VAS is not linear but exponential. In a study investigating rheumatic pain, comparison of the VAS scores with improvement in quality of life demonstrated that a reduction of even one VAS level was of benefit (16). Studies investigating the MCID of the different scales in patients with chronic pruritus are currently performed. In pain studies, VAS is ascribed high sensitivity, but VRS is thought to have not enough number categories to measure small changes (15). Reich et al. (17) therefore introduced one more category for pruritus assessment with VRS and could demonstrate that the cut-off levels of VAS and NRS correspond very well with the new VRS.

A total of 52 patients completed all scales at three time-points and missing values, i.e. number of questionnaires that have not been completed by patients, could be investigated. Interestingly, VAS showed the highest number of missing values at all time-points (8.0–17.3% of patients) depending on the age of patients (under 60 years of age: 8.7%; over 60 years of age: 16.1%). The missing values were lowest in NRS. Also, a decrease in missing values at visits 2 and 3 could be observed, probably due to a learning effect along with repeated competition of the tools. This is of high relevance for clinical trials. Missing values seem to occur because the scales are complex, not self-explanatory, and patients are unfamiliar with these tools. In particular, VAS presented only as a line without a landmark can be misunderstood. It seems that rating of a subjective sensation on a line or into a number is a more complex process, especially in elderly people. Explanation of the diary and a training session before the start of the study are recommended to increase data integrity.

In conclusion, high validity and concurrent validity in pruritus intensity assessment was shown not only by VAS, a traditional and widely-used instrument, but also by VRS and NRS. Discrimination of pruritus intensity

by VAS is more sensitive than NRS or VRS. In data evaluation, physicians have to be aware of confounding factors, such as the tendency of patients to rate the middle of the scales and patients' unfamiliarity with the tools provided. In particular, VAS showed a high rate of missing values, so that data integrity in clinical studies must be carefully checked. After repeat assessment, there were fewer missing values. We therefore also recommend using more than one scale and a combination of different scales to evaluate pruritus intensity, and a training session for using the VAS before starting a clinical trial. The sensitivity and required change for the tools being used remain to be investigated. However, these tools can be recommended for use in clinical trials and daily routine to assess the course of pruritus intensity.

ACKNOWLEDGEMENTS

We thank Rajam Csordas-Iyer for assistance in preparation of the manuscript.

The authors declare no conflicts of interest.

REFERENCES

1. Ständer S, Schäfer I, Phan NQ, Blome C, Herberger K, Heigel H, et al. Prevalence of chronic pruritus in Germany: results of a cross-sectional study in a sample working population of 11,730. *Dermatology* 2010; 221: 229–235.
2. Metz M, Ständer S. Chronic pruritus – pathogenesis, clinical aspects and treatment. *J Eur Acad Dermatol Venereol* 2010; 24: 1249–1260.
3. Ständer S, Weisshaar E, Mettang T, Szepletowski JC, Carstens E, Ikoma A et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. *Acta Derm Venereol* 2007; 87: 291–294.
4. Hayes MHS, Patterson DG. Experimental development of the graphic rating method. *Psychological Bulletin* 1921; 18: 98–99.
5. Flaherty SA. Pain measurement tools for clinical practice and research. *AANA J* 1996; 64: 133–140.
6. Miller MD, Ferris DG. Measurement of subjective phenomena in primary care research: the Visual Analogue Scale. *Fam Pract Res J* 1993; 13: 15–24.
7. Scott J, Huskisson EC. Graphic representation of pain. *Pain* 1976; 2: 175–184.
8. Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. *J Clin Nurs* 2005; 14: 798–804.
9. [No authors listed]. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. *Dermatology* 1993; 186: 23–31.
10. Aitken RC. Measurement of feelings using visual analogue scales. *Proc R Soc Med* 1969; 62: 989–993.
11. Litwin M. How to measure survey reliability and validity. Thousand Oaks, CA: Sage Publications, Inc.; 1995.
12. Keszei AP, Novak M, Streiner DL. Introduction to health measurement scales. *J Psychosom Res* 2010; 68: 319–323.
13. Carmines C, Zeller R. Reliability and validity. Thousand Oaks, CA: Sage Publications, Inc.; 1979.
14. Weisshaar E, Dalgard F. Epidemiology of itch: adding to

- the burden of skin morbidity. *Acta Derm Venereol* 2009; 89: 339–350.
15. Bijur PE, Silver W, Gallagher EJ. Reliability of the visual analog scale for measurement of acute pain. *Acad Emerg Med* 2001; 8: 1153–1157.
 16. Dhanani S, Quenneville J, Perron M, Abdollell M, Feldman BM. Minimal difference in pain associated with change in quality of life in children with rheumatic disease. *Arthritis Rheum* 2002; 47: 501–505.
 17. Reich A, Heisig M, Szepletowski JC. Visual Analogue Scale as a validated assessment of pruritus intensity. *Acta Derm Venereol* 2009; 89: 688.
 18. Szepletowski JC, Schwartz RA. Uremic pruritus. *Int J Dermatol* 1998; 37: 247–253.
 19. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. *Br J Dermatol* 2010; 162: 587–593.
 20. Majeski CJ, Johnson JA, Davison SN, Lauzon CJ. Itch Severity Scale: a self-report instrument for the measurement of pruritus severity. *Br J Dermatol* 2007; 156: 667–673.
 21. Wahlgren CF. Measurement of itch. *Semin Dermatol* 1995; 14: 277–284.
 22. Phan NQ, Ständer S. Assessment of pruritus intensity: correlation between visual analogue scale (VAS), numeric rating scale (NRS) and verbal rating scale (VRS) in patients with chronic pruritus. *Acta Derm Venereol* 2009; 89: 713.
 23. Jenkins HH, Spencer ED, Weissgerber AJ, Osborne LA, Pellegrini JE. Correlating an 11-point verbal numeric rating scale to a 4-point verbal rating scale in the measurement of pruritus. *J Perianesth Nurs* 2009; 24: 152–155.
 24. Wahlgren CF, Ekblom A, Hägermark O. Some aspects of the experimental induction and measurement of itch. *Acta Derm Venereol* 1989; 69: 185–189.
 25. Wahlgren CF. Children's rating of itch: an experimental study. *Pediatr Dermatol* 2005; 22: 97–101.
 26. Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic itch using the 'Eppendorf Itch Questionnaire'. *Int Arch Allergy Immunol* 2001; 124: 326–331.
 27. Yosipovitch G, Zucker I, Boner G, Gafter U, Shapira Y, David M. A questionnaire for the assessment of pruritus: validation in uremic patients. *Acta Derm Venereol* 2001; 81: 108–111.
 28. Weisshaar E, Apfelbacher C, Jäger G, Zimmermann E, Bruckner T, Diepgen TL, et al. Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. *Br J Dermatol* 2006; 155: 957–964.
 29. Ständer S. CME: Chronischer Pruritus Prinzipien der Diagnostik und Therapie. *Hautarzt* 2007; 58: 627–638.
 30. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. *Clin Exp Dermatol* 1994; 19: 210–216.
 31. Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. *J Am Acad Dermatol* 2008; 59: 234–244.
 32. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983; 67: 361–370.
 33. Blome C, Augustin M, Siepmann D, Phan NQ, Rustenbach SJ, Ständer S. Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. *Br J Dermatol* 2009; 161: 1143–1148.
 34. Benjamin K, Waterston K, Russell M, Schofield O, Diffey B, Rees JL. The development of an objective method for measuring scratch in children with atopic dermatitis suitable for clinical use. *J Am Acad Dermatol* 2004; 50: 33–40.
 35. Bringhurst C, Waterston K, Schofield O, Benjamin K, Rees JL. Measurement of itch using actigraphy in pediatric and adult populations. *J Am Acad Dermatol* 2004; 51: 893–898.
 36. Hon KL, Chiu LS, Lam MC, Choi CL, Chan S, Luk NM. Measurement of pruritus in a Chinese woman with pemphigoid gestationis using a wrist movement detector. *Int J Dermatol* 2008; 47: 64–67.
 37. Ebata T, Iwasaki S, Kamide R, Niimura M. Use of a wrist activity monitor for the measurement of nocturnal scratching in patients with atopic dermatitis. *Br J Dermatol* 2001; 144: 305–309.
 38. Savin JA, Paterson WD, Oswald I. Scratching during sleep. *Lancet* 1973; 2: 296–297.
 39. Aoki T, Kushimoto H, Hishikawa Y, Savin JA. Nocturnal scratching and its relationship to the disturbed sleep of itchy subjects. *Clin Exp Dermatol* 1991; 16: 268–272.
 40. Endo K, Sumitsuji H, Fukuzumi T, Adachi J, Aoki T. Evaluation of scratch movements by a new scratch-monitor to analyze nocturnal itching in atopic dermatitis. *Acta Derm Venereol* 1997; 77: 432–435.
 41. Mustakallio KK. Scratch radar for the measurement of pruritus. *Acta Derm Venereol Suppl* 1991; 156: 44.
 42. Summerfield JA, Welch ME. The measurement of itch with sensitive limb movement meters. *Br J Dermatol* 1980; 103: 275–281.
 43. Felix R, Shuster S. A new method for the measurement of itch and the response to treatment. *Br J Dermatol* 1975; 93: 303–312.
 44. Ebata T, Aizawa H, Kamide R, Niimura M. The characteristics of nocturnal scratching in adults with atopic dermatitis. *Br J Dermatol* 1999; 141: 82–86.
 45. Talbot TL, Schmitt JM, Bergasa NV, Jones EA, Walker EC. Application of piezo film technology for the quantitative assessment of pruritus. *Biomed Instrum Technol* 1991; 25: 400–403.
 46. Molenaar HA, Oosting J, Jones EA. Improved device for measuring scratching activity in patients with pruritus. *Med Biol Eng Comput* 1998; 36: 220–224.
 47. Bijak M, Mayr W, Rafolt D, Tanew A, Unger E. Prurito-meter 2: portable recording system for the quantification of scratching as objective criterion for the pruritus. *Biomed Tech (Berl)* 2001; 46: 137–141.
 48. Stener-Victorin E, Lundeberg T, Kowalski J, Opdal L, Sjöström J, Lundeberg L. Perceptual matching for assessment of itch; reliability and responsiveness analyzed by a rank-invariant statistical method. *J Invest Dermatol* 2003; 121: 1301–1305.
 49. Hägermark O, Wahlgren CF. Some methods for evaluating clinical itch and their application for studying pathophysiological mechanisms. *J Dermatol Sci* 1992; 4: 55–62.